155. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Community-Acquired Pneumonia and Community-Acquired Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2014-2020)

BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibacterial approved in the US for the treatment of community-acquired bacterial pneumonia (CABP). DLX is indicated to treat CABP caused by Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), Haemophilus parainfluenzae (HP...

Descripción completa

Detalles Bibliográficos
Autores principales: Shortridge, Dee, Streit, Jennifer M, Huband, Michael D, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644506/
http://dx.doi.org/10.1093/ofid/ofab466.155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644506/
http://dx.doi.org/10.1093/ofid/ofab466.155

Ejemplares similares